November 20th 2024
Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for procedural sedation during cataract surgery. The results support a regulatory submission, with potential to revolutionize sedation practices in various medical specialties.
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (CME/CNE Credit)
View More
Community Practice Connections™: Mastering the Multidisciplinary Management of Glaucoma—Understanding Advances in the Spectrum of Treatment Innovation (COPE Credit)
View More
(COPE) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Advancing Treatment in Neovascular Retinal Disease with Novel Therapies: Insights and Strategies from Latest Real-World and Clinical Data
View More
Rapid Reviews in Retina™: Emerging Updates from Fall 2023 – Addressing the Wealth of New Data in Treatments for nAMD and DME
View More
(CME) Stratifying the Spectrum of Care in Glaucoma Management – Advancing Treatment with a Vast Armamentarium
View More
(CME) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(COPE) Community Practice Connections™: Optimizing Multidisciplinary Care for nAMD & DME – Expert Perspectives with New Dosing Strategies on the Horizon
View More
(CME) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(COPE) Community Practice Connections™: Advancing Management Strategies in Geographic Atrophy– Mapping Out the Continuum of Care in a New Era of Transformative Treatment
View More
(CME) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
(COPE) Key Advances in Cataract Surgery – Applications for New Technologies in an Ever-Changing Landscape
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (CME Credit)
View More
Managing Ocular Toxicities in Patients With Cancer: Understanding ADCs and the ECP’s Role in Collaborative Management Therapy on the Horizon (COPE Credit)
View More
SimulatED™: Applying Advanced Treatment for nAMD & DME - Simulating New Strategies for Clinical Management
View More
EnVision Summit
February 14-17, 2025
Register Now!
Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments
March 16, 2025
Register Now!
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Injectable lens possible solution to restore accommodation
October 15th 2003Groningen, The Netherlands-Early preclinical studies are yielding promise that an injected, artificial, capsule-filling lens may offer a possible solution for restoring accommodative ability lost in presbyopia or pseudophakia.
Read More
IOL implantation system yields ultra-small-incision surgery
October 15th 2003Nuremberg, Germany-The Acri.Smart 48S IOL implanted with the Acri.Glide/Acri.Shooter system (Acri.Tec, Berlin, Germany) enables cataract surgery to be performed completely with the benefits of ultra-small-incision techniques, said Wolfram Wehner, MD.
Read More
CIBA Vision solutions OK for silicone hydrogel lens
October 15th 2003Atlanta-The FDA is allowing CIBA Vision to tell consumers they may use AOSEPT Clear Care and SOLO-care Plus with silicone hydrogel contact lenses. Clear Care is the first and only no-rub, peroxide-based formula in the United States to receive clearance for this indication.
Read More
IOL filters, protects against harmful UV, blue-light hazard
October 1st 2003London-Exposure of the retina to excessive blue light is hazardous to the pigment epithelial cells and may underlie the increase in the prevalence of age-related macular degeneration (AMD) in individuals in the eighth and ninth decades of life.
Read More
Hybrid design brings best of both worlds in IOL edges
October 1st 2003The Clariflex and Sensar AR40e IOLs (AMO) are physician-friendly implants that provide patients with unsurpassed optical performance because of their proprietary OptiEdge (AMO) design, agree cataract surgeons who favor the OptiEdge IOLs.
Read More
Aspheric lens helps improve quality of vision
October 1st 2003Visual performance after cataract surgery is superior in eyes with the aspheric IOL implanted compared with other commonly used foldable implants, according to the results of a blinded, prospective, randomized study presented by Robert M. Kershner, MD, FACS.
Read More
Exciting progress continues to be made in IOL technology. However, as researchers develop new materials and designs, Nick Mamalis, MD, cautioned that care must to be taken to avoid revisiting old problems so that, as the Barenaked Ladies song title says, "Everything Old is New Again."
Read More
Vision outcomes create optimistic expectation for spectacle independence
October 1st 2003Editor's Note: The CrystaLens was recommended for approval by the FDA's Ophthalmic Devices Advisory Panel in late May. The lens may be commercially available later this year or early 2004. Dr. Doane's presentation was given at the annual meeting of the American Society of Cataract and Refractive Surgery prior to the recommendation.
Read More
Presbyopic patients almost spectacle-free after lens exchange procedure
October 1st 2003Mainz, Germany-Refractive lens exchange with implantation of a foldable, multifocal IOL is a safe, effective, and stable surgical option for the treatment of hyperopia and myopia in the presbyopic population.
Read More
Hydrophilic IOL yields low incidence of Nd:YAG capsulotomy
October 1st 2003New York-The 1-year follow-up of the Hydroview IOL (Bausch & Lomb) indicates that the lens is safe and provides excellent postoperative visual outcomes, a low incidence of Nd:YAG capsulotomy, and no cases of decentration, according to Douglas Grayson, MD, FACS.
Read More
European study's interim results favorable for myopic PRL
September 15th 2003San Francisco-An interim analysis of data from an ongoing European multicenter study of the Phakic Refractive Lens (PRL, CIBA Vision/Medennium) indicates that the posterior chamber implant is a safe, effective, and predictable method for correcting high myopia, said Bo Philipson, MD, PhD, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Read More
Silicone punctum plugs improve ocular surface in dry eye
September 15th 2003Fort Lauderdale, FL-Blocking the canaliculus with silicone punctal plugs has been shown to improve the stability of the tear film, decrease the ocular surface staining scores and squamous metaplasia grades, and increase the goblet cell density, according to Dilek Dursun, MD.
Read More
Cosmetic botulinum toxin appealing to patients, physicians
September 1st 2003Kansas City, KS-Incorporating cosmetic botulinum toxin type A (Botox, Botox Cosmetic, Allergan) treatment into an ophthalmic practice's realm of services can be very satisfying for patients and the practitioner, said Jemshed A. Khan, MD.
Read More
NSAID helps reduce pain after cataract, refractive surgery
August 15th 2003Duluth, GA-Diclofenac sodium ophthalmic solution (Voltaren, Novartis Ophthalmics) is a nonsteroidal anti-inflammatory drug (NSAID) with a proven track record. It is the drug of choice to relieve pain following cataract or refractive surgery, and it has maintained that position despite the increased incidence of corneal melt associated with a generic version of the drug, according to Douglas A. Katsev, MD. He described diclofenac as a staple in his private practice in Santa Barbara, CA.
Read More
ESCRS to focus on four symposia during annual meeting
August 15th 2003Munich, Germany-The 2003 annual gathering of the European Society of Cataract and Refractive Surgeons (ESCRS) will open on Saturday, Sept. 6 and continue through Wednesday, Sept. 10, at the ICM Congress Centre, in this city in the heart of Bavaria.
Read More
IOL design mimics optic shape change of natural lens
August 1st 2003San Francisco-A novel accommodating IOL (FlexOptic, Quest Vision) designed to mimic the natural crystalline lens through an ability to change optic sphericity is a promising new alternative to treating presbyopia, with the potential for superior efficacy and safety relative to other options for surgical accommodative correction, said John D. Hunkeler, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
Time-release drugs ease burden of drops
July 15th 2003San Francisco-Patient noncompliance can be overcome with the delivery of medication to the eye with intraocular time-release systems, according to James P. Gills, MD, who spoke during the Innovator's Session at the American Society of Cataract and Refractive Surgery annual meeting.
Read More
Silicone IOL well tolerated in high-risk glaucomatous eyes
July 1st 2003San Francisco-The ClariFlex third-generation silicone IOL (AMO) is well tolerated in high-risk glaucomatous eyes, and the Unfolder Silver-Z insertion system (AMO) performs well in these eyes, with a very low incidence of cartridge jams or damaged IOLs, accord-ing to Thomas W. Samuelson, MD.
Read More
IOL edge design helps to reduce capsulotomy rates at 1 year
July 1st 2003San Francisco-The Sensar IOL (AMO) with OptiEdge provides patients with excellent visual acuity, and after 1 year, it is associated with a higher incidence of clear posterior capsules and a lower rate of Nd:YAG capsulotomy compared with the parent model without OptiEdge, reported William J. Fishkind, MD, at the American Society of Cataract and Refractive Surgery annual meeting.
Read More